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Summary
Background.— An increasing number of patients with infective endocarditis (IE) are operated
on before the end of the ﬁrst week of antimicrobial therapy. The mortality and morbidity of
this speciﬁc group are unknown.
Aims.— To evaluate the outcome of patients with IE requiring cardiac surgery performed within
the ﬁrst week of antimicrobial therapy.
Methods.— All consecutive patients with a deﬁnite diagnosis of IE operated on within the
ﬁrst week of antimicrobial therapy were followed prospectively. Endpoints were in-hospital
mortality and a combined endpoint of long-term cardiovascular death, recurrence and non-
infective postoperative valvular dysfunction (PVD). The three main conditions requiring surgery,
namely haemodynamic impairment, high embolic risk and periannular extension, were tested
as potential predictors of outcome after adjustment for relevant variables.
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Conclusion.— Le risque de décès, de récurrences et de DVP ne paraît pas excessif lorsque la
chirurgie a du être effectuée après un bref délai après le début de l’antibiothérapie. Cepen-
dant, en présence d’une extension périannulaire, on doit s’attendre à un risque plus élevé
d’évènements postopératoires.
© 2008 Elsevier Masson SAS. All rights reserved.
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alvular surgery performed during the active phase of infec-
ive endocarditis (IE) is indicated in an increasing proportion
f patients and currently ranges from 30 to 60% [1,2].
ecent changes in the epidemiological and microbiologi-
al proﬁle of the disease could explain this trend, with an
ncrease in complicated situations due to a greater inci-
ence of more virulent microorganisms and intracardiac
aterial infections [1,3—5]. Several works have deter-
ined the prognosis of patients who underwent surgery
efore the end of antimicrobial therapy [6—10]; most
howed that the advent of surgical therapy for com-
licated IE has been associated with reduced mortality
6,7,9]. Thus, these results have encouraged physicians
o offer surgical treatment for an increasing number of
atients. Although the indications for surgery are well
eﬁned in international guidelines [11—13], no consen-
e
w
a
t
pus exists on the optimal timing of surgical intervention
ecause of a lack of evidence-based data. However, in
atients with the most severe complications, surgery can-
ot be delayed and must be performed as soon as possible,
requently before the end of the ﬁrst week of antimicrobial
herapy [2]. This very early surgical management, which can
mprove prognosis, raises the concern of the theoretical risk
f both high operative mortality and recurrence or postop-
rative valve dysfunction (PVD) by implanting material into
nfected tissues. The rates of mortality and recurrence in
atients who underwent early surgery regardless of the tim-
ng of the intervention is known and ranges from 8 to 36%
6,14,15] and from 3 to 17% [14,16,17], respectively. How-F. Thuny et al.
Results.— Among the 95 patients included, surgery was performed a median time of 3 days after
starting antimicrobial therapy. In-hospital mortality was 15%. The 3-year cumulative rates of
the combined endpoint and of cardiovascular death were 38± 7% and 27± 7%, respectively.
Recurrence occurred in 12% and PVD in 7%. Periannular extension was the main predictor of
in-hospital death and the combined endpoint.
Conclusion.— Despite the short time between starting antimicrobial therapy and performing
surgery, the risk of death, recurrence and PVD does not appear excessively high. In the presence
of periannular extension, however, surgery is associated with a greater risk of postoperative
events.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— Un nombre croissant de patients atteints d’endocardite infectieuse (EI) sont opérés
avant la ﬁn de la première semaine d’antibiothérapie. La morbimortalité postopératoire de ce
groupe particulier de patients reste méconnue.
Objectifs.— Nous avons analysé le devenir des patients atteints d’EI opérés dans la première
semaine d’antibiothérapie.
Méthodes.— Tous les patients consécutifs présentant le diagnostic certain d’EI et opérés dans
le courant de la première semaine d’antibiothérapie ont été suivis de fac¸on prospective.
Les critères de jugement étaient la mortalité hospitalière et un critère combiné incluant les
décès à long terme d’origine cardiovasculaire, les récurrences d’EI et les dysfonctions valvu-
laires postopératoires non infectieuses (DVP). Les trois principales indications chirurgicales,
à savoir l’instabilité hémodynamique, le risque embolique élevé et l’extension périannulaire
de l’infection, ont été testées comme de potentiels facteurs prédictifs d’évènements après
l’ajustement aux autres variables pertinentes.
Résultats.— Parmi les 95 patients inclus, la chirurgie a été réalisée après un délai médian
de trois jours. La mortalité hospitalière a été de 15%. Les taux cumulés à trois ans
du critère combiné et de décès cardiovasculaires ont été respectivement de 38± 7%
et 27± 7%. Une récurrence est survenue chez 12% des patients et une DVP chez 7%.
L’extension périannulaire était le principal facteur prédictif de mortalité hospitalière
et de survenue d’un décès cardiovasculaire à long terme, d’une récurrence ou d’une
DVP.ver, the outcome of the speciﬁc growing group of patients
ith IE operated on before the end of the seventh day of
ntimicrobial therapy is unknown. Therefore, we chose to
ake advantage of a large, prospectively enrolled cohort of
atients with IE to analyse in-hospital and long-term out-
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[26] and Staphylococcus aureus [24]). For in-hospital mor-1st week of antimicrobial therapy during infective endocard
comes of those who underwent surgery before the end of
the ﬁrst week of antimicrobial therapy.
Methods
Patient sample
All consecutive patients admitted to our centre between
January 1992 and June 2007 with a deﬁnite diagnosis of IE
[18] were eligible and were included prospectively in our
database. Cases of IE included before 2000, before the mod-
iﬁed Duke criteria had been introduced, were screened and
the new case deﬁnition was applied retrospectively. Patients
operated on within the ﬁrst week after the beginning of
antimicrobial therapy formed the study sample. Patients
with only pacemaker or deﬁbrillator IE were excluded. This
study was approved by our institutional review board, and
informed consent was obtained from all patients. No patient
initially included was excluded from analyses after initial
assessment.
Clinical, microbiological and
echocardiographic data
The following clinical parameters were collected prospec-
tively at diagnosis: age, sex, valvular prosthesis, intravenous
drug abuse (IVDA), HIV infection, diabetes, cancer, Charl-
son comorbidities index [19], congestive heart failure (CHF),
stroke, serum creatinine, Glasgow coma scale (GCS) and
EuroSCORE [20]. Occurrence of cerebrovascular complica-
tions was screened by a systematic cerebral computed
tomography (CT) scan at study entry.
Blood cultures and serologies were collected system-
atically at admission. In addition, direct analysis and
polymerase chain reaction (since 1995) were performed on
each explanted valve.
All patients underwent both transthoracic and transoe-
sophageal echocardiograms in our laboratory within 24 h
of admission. Data were stored electronically and used as
noted at the time of the original examination without alter-
ation. The degree of aortic and mitral regurgitation was
assessed semiquantitatively or by quantitative methods for
the most recent patients and was classiﬁed as mild, moder-
ate or severe [21]. Periannular extension (PE) was deﬁned
as described previously [22,23].
Surgery
Surgery was performed within the ﬁrst week of the appropri-
ate antimicrobial therapy and was indicated for at least one
of the following three recommended conditions [11—13]:
• haemodynamic impairment including CHF, or severe left
valvular regurgitation without heart failure, but with evi-
dence of elevated end-diastolic or left atrial pressures;
• high embolic risk due to emboli with persistent greater
than 10mm vegetation or greater than 15mm vegetation
without emboli [2];
• presence of a PE.
In cases of ischaemic stroke, diagnosis was conﬁrmed
by an experienced neurologist and a cerebral CT scan was
t
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erformed systematically 24 h before surgery to ensure the
bsence of haemorrhage. In cases of coma, the decision to
perate was made according to the neurological prognosis,
omorbidities and severity of haemodynamic impairment.
During the operation, when the infection was limited
o the cusps of native aortic valves or to the leaﬂets of
ortic prostheses, the surgery consisted of simple valve
eplacement by conventional prostheses or implantation of
n aortic homograft, at the discretion of the surgeon. When-
ver infection extended to the surrounding structures, or in
ase of annulus abscess with annulus disruption, surgery con-
isted of extensive resection of all infected tissues and their
econstruction by either glutaraldehyde-ﬁxed autologous or
ovine pericardium, Dacron® fabrics or aortic homograft.
n cases of mitral localization, repair was always preferred
hen possible, most often with excision of vegetation and
econstruction with autologous pericardium. If valve recon-
truction was not possible, a conventional prosthesis was
mplanted.
ndpoints
tudy endpoints were in-hospital death and a combined
ndpoint of cardiovascular death, IE recurrence (relapses
nd reinfections) and non-infective PVD during hospital-
zation and after discharge. Cardiovascular mortality was
eﬁned as death resulting from the IE episode or the
urgery during hospitalization and after discharge. Recur-
ence was deﬁned as all the new episodes of IE occurring
fter surgery. PVD included valve repair failure and mod-
rate or severe prosthesis dysfunction not related to IE
ecurrence. The events (death, recurrence and PVD) were
ollected prospectively during routine follow-up visits and
chocardiography was performed systematically after hos-
ital discharge and by contacting patients’ physicians.
ollow-up information on vital status was obtained from
arch to April 2008.
tatistical analysis
ategorical variables are presented as percentages and
ere analysed using the Chi2 test or Fisher’s exact test
two-tailed). Continuous variables are presented as means
ith standard deviations (S.D.) or medians with ranges and
ere analysed using Student’s t-test or the Mann—Whitney
est. Time-to-event distributions are summarized with
aplan—Meier curves.
The three main conditions requiring surgery (haemody-
amic impairment, high embolic risk and PE) were tested
s the variables potentially predictive of the endpoints in
ingle-variable analysis and after adjustment (multivariable
nalysis) for variables known to be important predictors
f outcome (age [24], sex [24], comorbidity index [6],
uroSCORE [20], prosthetic valve IE [5], stroke [25], GCSality, multivariable analysis was performed using logistic
egression. For the combined endpoint, single and multi-
ariable analyses used Cox proportional-hazards regression.
-values < 0.05 were considered signiﬁcant. All analyses
ere performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
6 F. Thuny et al.
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Figure 1. Time to cardiovascular death, recurrence and non-
infective postoperative valvular dysfunction (combined endpoint)
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aseline characteristics
reoperative characteristics
mong 534 consecutive patients admitted with a deﬁnite
iagnosis of IE, 342 (64%) had at least one theoretical indica-
ion for surgery. Fifty-one (10%) patients underwent surgery
t the end of antimicrobial therapy or were denied surgery
ecause of excessive operative risk or they refused the pro-
edure. Among the 291 (55%) patients operated on during
he course of antimicrobial treatment, 95 patients under-
ent surgery within the ﬁrst week of treatment and formed
ur prospective cohort.
The mean age of the study population was 53± 16 years
nd 16% were older than 70 years. Patients’ baseline
haracteristics and microbiological ﬁndings are reported
n Tables 1 and 2, respectively. Indications for surgery
ere haemodynamic impairment in 75 (79%) patients, high
mbolic risk in 56 (59%), presence of PE in 40 (42%) and
ore than one condition in 61 (64%). Of the 75 patients with
aemodynamic impairment, 44 had heart failure (ﬁve with
ardiogenic shock), which was the consequence of an acute
evere left valvular regurgitation or ﬁstula (3 patients), and
1 (33%) had severe left valvular regurgitation without heart
ailure. Diagnosis of PE was conﬁrmed in all 40 patients with
n echocardiographic suspicion (aortic in 31 patients and
itral in nine). Among the 56 patients with high embolic
isk, 30 had a previous embolism (cerebral in 12 patients)
ith persistent greater than 10mm vegetation and 26 had
reater than 15mm vegetation without embolism. Vege-
ation was the only reason for surgery in eight patients
8%).
urgical procedures
urgery was performed a median of 3 (range 0—7) days after
he start of medical treatment. Twenty-four (25%) patients
nderwent surgery within 24 h. In 61 aortic localizations,
he types of valvular substitute included bioprostheses in
8, mechanical prostheses in six and aortic homografts
n 26 patients. Vegetectomy was possible in one case.
mong 50 mitral localizations, valve repair was possible in
0 patients (49% of the native mitral valve IE) and a bio-
rosthesis or mechanical prosthesis was implanted in 24 and
ix patients, respectively.
n-hospital mortality
ourteen (15%) patients died postoperatively before dis-
harge a median of 18 (range 5—75) days after surgery.
xcess mortality was noted in prosthetic-valve IE (PVE) com-
ared with native-valve IE (NVE) (30% vs 11%, P = 0.07).
auses of death were multiorgan failure (7 cases), postoper-
tive myocardial infarction (3 cases), septic shock (2 cases)
nd peroperative death (one case of irreparable abscess and
ne case of intractable haemorrhage). Only one patient with
reoperative cardiogenic shock died. Three patients died
mong the 24 who underwent surgery less than 24 h after
he beginning of antimicrobial therapy.
Considering the three main conditions requiring surgery,
xcess mortality was observed in patients operated on with a
a
o
v
tccording to the presence of periannular extension (PE).
E (23% vs 9%, P = 0.07). After adjustment for relevant vari-
bles (see Methods section) and the two other indications
or surgery, the only predictors of in-hospital mortality were
E (adjusted odds-ratio [OR] 6.3; 95% conﬁdence interval
CI] 1.27—30.9, P = 0.02) and GCS (adjusted OR 0.4; 95%CI
.18—0.89, P = 0.02) (Table 3). The main cause of death in
atients with PE was multiorgan failure (six of nine deaths).
Among the 10 patients with preoperative stroke, only
ne had postoperative increase of cerebral damage. Two
atients had postoperative stroke.
ong-term cardiovascular mortality,
ecurrence and non-infective PVD
he median length of follow-up was 1 year (range 0.01—10).
ollow-up was complete in all patients. A total of 20 patients
ied during follow-up. Six patients died after discharge (IE
ecurrence in three, severe heart failure in two and cancer in
ne). The cause of death was cardiovascular in 19 patients.
E recurred in 11 (12%) patients, ﬁve of whom required
eoperation. PVD occurred in seven patients (7%). Causes of
ysfunction were failure of mitral valve repair (2 patients),
echanical prosthesis desinsertion (2 patients), pseudoa-
eurysm on homograft suture (2 patients) and moderate to
evere aortic regurgitation after vegetectomy (1 patient).
ll were reoperated except the last, who required close
onitoring.
The combined endpoint occurred in 32 patients (29% for
VE vs 50% for PVE, P = 0.03). Cumulative rates of the com-
ined endpoint were 30± 5% at 6months, 33± 5% at 1 year
nd 38± 7% at 3 years (Fig. 1).
Considering the three main conditions requiring surgery,
n excess of events was observed only in patients
perated on with PE. After adjustment for relevant
ariables and the two other indications for surgery,
he only predictors of the combined endpoint were PE
1st week of antimicrobial therapy during infective endocarditis 691
Table 1 Clinical, laboratory and echocardiography ﬁndings in 95 patients with infective endocarditis operated on within
the ﬁrst week of antibiotic therapy.
All patients
(n = 95)
Native-valve infective
endocarditis (n = 75)
Prosthetic-valve infective
endocarditis (n = 20)
pa
Age, years (mean± S.D.) 53± 16 52± 17 56± 14 0.58
Men 69 (73) 54 (72) 15 (75) 0.78
Comorbidity index > 2 33 (35) 26 (35) 7 (35) 0.97
HIV infection 1 (1) 1 (1) 0 (0) 1.0
History of cancer 13 (14) 11 (15) 2 (10) 0.72
Diabetes mellitus 9 (10) 7 (9) 2 (10) 1.00
Serum creatinine > 20mg/L 12 (13) 7 (9) 5 (25) 0.12
Intravenous drug abuse 12 (13) 12 (16) 0 (0) 0.06
Heart failure 44 (44) 38 (52) 6 (30) 0.1
Stroke 10 (11) 6 (8) 4 (20) 0.21
EuroSCORE (mean± S.D.) 8.9± 2.7 8.3± 2.3 11.1± 2.9 < 0.001
Glasgow coma scale (mean± S.D.) 14.8± 0.8 14.8± 0.9 14.8± 0.7 1.0
Vegetation 77 (81) 66 (88) 11 (55) 0.002
Left ventricular ejection fraction < 45% 2 (2) 1 (1) 1 (5) 0.38
Valve localization
Aortic 61 (64) 48 (64) 13 (65) 0.93
Mitral 50 (53) 39 (52) 11 (55) 0.81
Multivalvular 22 (23) 18 (24) 4 (20) 1.0
Indications for surgery
Haemodynamic impairmentb 75 (79) 62 (83) 13 (65) 0.12
High risk of embolismc 56 (59) 47 (49) 9 (45) 0.15
Periannular extensiond 40 (42) 27 (36) 13 (65) 0.02
Time to surgery, median (range) days 3.0 (0—7) 3.0 (0—7) 2.5 (0—7) 0.78
a Comparison between patients with native-valve and prosthetic-valve infective endocarditis.
b Including CHF, or severe left valvular regurgitation without heart failure, but with evidence of elevated end-diastolic or left atrial
pressures.
c Emboli with persistent greater than 10mm vegetation or greater than 15mm vegetation without emboli.
ed Abscess with or without pseudo aneurysm or ﬁstula.
(adjusted hazard ratio [HR] 3.1; 95%CI 1.32—7.14, P = 0.009)
and GCS (adjusted HR 0.66; 95%CI 0.47—0.92, P = 0.02)
(Table 4).
Cumulative cardiovascular mortality was 27± 7% at
3 years. Considering the three main indications for surgery,
p
(
e
Table 2 Microbiological ﬁndings of 95 patients with infective e
therapy.
Microbiological ﬁnding, n (%) All patients
(n = 95)
Native-v
endocard
Staphylococcus aureus 23 (24) 18 (24)
Viridans streptococci 17 (18) 15 (20)
S. bovis 13 (14) 11 (15)
Enterococci 12 (13) 11 (15)
Coagulase-negative staphylococci 5 (5) 2 (3)
Others 14 (15) 10 (13)
Negative blood culturesb 17 (18) 10 (13)
a Comparison between patients with native-valve and prosthetic valve
b Among 17 negative blood cultures, the microorganism remained unk
the explanted valve and serology data.xcess cardiovascular mortality was observed only in
atients with PE (HR 2.7; 95%CI 1.05—6.84, P = 0.038)
Fig. 2).
Of the eight patients who underwent surgery only for high
mbolic risk, none died, recurrence occurred in one patient,
ndocarditis operated on within the ﬁrst week of antibiotic
alve infective
itis (n = 75)
Prosthetic-valve infective
endocarditis (n = 20)
pa
5 (25) 1.0
2 (10) 0.51
2 (10) 0.73
1 (5) 0.45
3 (15) 0.06
4 (20) 0.48
7 (35) 0.04
infective endocarditis.
nown in 10 (11%) patients despite polymerase chain reaction on
692 F. Thuny et al.
Table 3 Predictors of in-hospital mortality (multivariable analysis).
Adjusted odds-ratio 95% conﬁdence interval P
Periannular extension 6.3 1.27—30.9 0.02
Haemodynamic impairment 2.9 0.20—44.1 0.43
High embolic risk 0.9 0.20—3.97 0.88
Age 1.01 0.95—1.08 0.68
Male sex 1.0 0.22—5.02 0.96
Comorbidity index > 2 2.7 0.35—20.2 0.34
Stroke 0.1 0.002—7.41 0.33
Prosthetic valve infective endocarditis 3.2 0.50—20.9 0.22
Staphylococcus aureus 1.5 0.29—7.34 0.64
Glasgow coma scale 0.4 0.18—0.89 0.02
EuroSCORE 1.08 0.76—1.53 0.69
Table 4 Predictors of the combined endpoint (cardiovascular death, infective endocarditis recurrence and non-infective
surgical procedure dysfunction) by Cox multivariable analysis.
Adjusted hazard ratio 95% conﬁdence interval P
Periannular extension 3.1 1.32—7.14 0.009
Haemodynamic impairment 0.9 0.28—2.84 0.84
High embolic risk 1.0 0.43—2.26 0.96
Age 1.0 0.96—1.02 0.62
Male sex 0.6 0.24—1.56 0.31
Comorbidity index > 2 1.9 0.60—5.85 0.28
Stroke 0.5 0.12—2.31 0.40
Prosthetic valve infective endocarditis 1.5 0.46—4.74 0.52
Staphylococcus aureus 1.3 0.53—3.23 0.56
Glasgow coma scale 0.66 0.47—0.92 0.02
EuroSCORE 1.12
Figure 2. Time to cardiovascular death according to the presence
of periannular extension (PE).
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10.91—1.36 0.28
VD in one patient and an embolic event (postoperative
etinal embolism) occurred in one.
mpact of type of surgery
mong the 41 patients with native mitral valve IE, repair
as performed in 20 (49%) patients. In-hospital mortality
as 5% after mitral valve repair and 19% after replacement
P = 0.34). No difference was observed between the two pro-
edures in terms of the combined endpoint (P = 0.15). Among
he 61 patients with aortic IE, no signiﬁcant difference was
bserved according to the type of surgery (conventional
rosthesis vs homograft) in terms of in-hospital mortality
12% vs 23%, P = 0.31) and the combined endpoint (P = 0.82).
iscussion
o our knowledge, this is the largest observational study
o analyse the outcomes of patients with IE operated on
ithin the ﬁrst week of antimicrobial therapy. We showed
hat mortality and morbidity are not excessively high when
urgery must be performed despite a short time after the
eginning of antimicrobial therapy. Operative mortality was
5%, recurrence occurred in 12% of cases, PVD in 7% and
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the 3-year rate of cardiovascular death, recurrence and PVD
was 38%. In our series, PE was a strong predictor of a worse
outcome.
Indications for urgent surgery
Although the beneﬁcial effect of surgery in patients with
complicated IE has been demonstrated, particularly in the
case of heart failure [6,7,9], the optimal timing of the
operation is a crucial question that remains unanswered by
international guidelines [11—13]. The beneﬁt of operating
very early should be balanced against a theoretical higher
risk of perioperative death and prosthetic infection. Haemo-
dynamic impairment, high risk of embolism and PE are the
three main conditions where an indication to perform urgent
surgery may be discussed. CHF is the most important indi-
cation for a very early operation because it has the greatest
impact on prognosis [27], and a large propensity analysis
demonstrated a signiﬁcant reduction of death when surgery
had been performed [6]. Although surgery is recommended
in other situations, the evidence of a beneﬁcial effect and
the optimal timing in patients without heart failure are less
clear. However, since a poor surgical outcome is predicted
by heart failure, it is recommended to perform surgery in
patients without heart failure but with acute severe valvu-
lar regurgitation associated with elevated left end-diastolic
pressures. Moreover, in cases of large vegetations the beneﬁt
of surgery seems to be greatest in the ﬁrst week of antimi-
crobial therapy when the risk of embolism is the highest
[24,28,29]. Similarly, recent studies have shown convincing
evidence that the presence of abscesses, with or without ﬁs-
tula, is associated with poor prognosis [30—32]. Early surgery
is recommended in this high-risk subgroup to avoid heart
failure and atrioventricular block [33,34].
In our study haemodynamic impairment with or without
heart failure was obviously the most frequent indication for
surgery. The high number of patients operated on with a high
risk of embolism (59%) reﬂects our policy to prescribe an ear-
lier surgical treatment when large vegetations are present
on admission. This trend was also observed in the recent
European survey where the size of vegetation was one of
the reasons for surgery during the active phase of infection
in 48% of cases [2]. However, vegetation size was the sole
indication for surgery in only 8% of cases in our series and in
6% in the European survey (6%). Thus, a high risk of embolism
is rarely the only reason for surgery, but it points toward an
earlier operation when associated with other indications.
Outcome after very early surgery
In the current era, more patients must be operated in an
urgent setting after diagnosis because of an increased rate
of complicated episodes of IE [1,2]. Several works have
determined the prognosis of patients who underwent surgery
before the end of antimicrobial therapy [6,9,10,14,15,35],
but in these series the ranges in timing of surgery were wide
because of the heterogeneous seriousness of the disease.
Our study analysed the outcome of a more homogenous high-
risk population of patients who only required surgery before
the end of the ﬁrst week of antimicrobial treatment. The
patients followed in the present work had a high-risk pro-
ﬁle because several predictors of mortality were present
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n most. Indeed, S. aureus was the most frequent microor-
anism, 46% of patients had heart failure, 11% experienced
troke, 42% had an abscess and the mean EuroSCORE was
igh. However, despite this proﬁle and the fewdays under
ntimicrobial therapy, mortality and morbidity were not as
igh as expected. In-hospital mortality was 15% and 6-month
nd 1-year CV mortality were 15 and 19%, respectively,
hich are comparable with most of the rates published in
eries where the patients were included irrespective of the
iming of surgery during the active phase [1,2,6,14]. In the
uroHeart survey postoperative in-hospital mortality was
5.6% [2].
In the recent series by Revilla et al. [15], a higher rate of
n-hospital death (36%) was observed. In this work, surgery
as performed at different times during the whole active
hase of infection; the persistence of fever and/or positive
lood cultures after 7 days of appropriate antibiotic ther-
py was a strong predictor of mortality. An examination of
uch results suggests that the lower rate of in-hospital death
bserved in our study could be explained by the shorter
nterval between the beginning of the antimicrobial ther-
py and surgery. Such a short interval, allowing for early
nd extensive removal of all infected tissues, could indeed
ave helped to avoid persistent infection.
Recurrence of IE is a serious complication since reinfec-
ion usually occurs on a prosthetic valve. Some previous
eries suggested that the risk of recurrence depended on
he time between the beginning of antimicrobial therapy
nd the surgery [36]. In our study, despite early implanta-
ion of material into infected tissues, recurrences occurred
n 12% of patients, which is comparable with the results
bserved in patients operated on at any time during the
ctive phase of infection. Postoperative recurrent IE was
eported in 22.5% in the study by Renzulli et al. [17], and
he 15-year rate of recurrence was 14% in a recent paper
y David et al. [14]. Our satisfactory rate of recurrence
ssociated with a low rate of PVD is another encourage-
ent to perform surgery without delay in cases of important
omplications.
These unexpected and relatively satisfactory results may
e explained by aggressive and very early surgical indica-
ions, which have long been the policy of our department.
ery early surgery might avoid occurrence of intractable
eart failure, new episode of embolization and excessive
xtension of anatomical lesions. We identiﬁed the presence
f PE at the time of surgery as the only indication for surgery
hat predicted mortality and morbidity. In our opinion, this
esult should not discourage others to operate on patients
ith PE because the beneﬁt of surgery might be greater than
he risk. When surgery is performed in this context, patients
hould be monitored closely by physical examination and
chocardiography. However, the poor prognosis associated
ith a low GCS might be a situation in which surgery should
e postponed or contraindicated.
imitationsecause of the absence of a comparison of outcome accord-
ng to timing of surgery, the present study could not
etermine the optimal interval between the beginning of
ntimicrobial therapy and the surgical treatment. Either
randomized trial or at least a propensity analysis would
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e necessary. Since most severely affected patients are
ften directed to earlier surgery, a randomized alloca-
ion of treatment would be ethically unacceptable. Despite
hese limitations, our study is the largest to determine pre-
isely the rate of death and postoperative complications
f patients who required surgery within the ﬁrst week of
edical treatment.
onclusion
n cases of severe complicated endocarditis, very early sur-
ical management may be successfully performed within the
rst week of antimicrobial therapy without a very high rate
f mortality and morbidity. In the presence of PE, the oper-
tion should be expected to involve a greater risk of death,
ecurrence and non-infective PVD. However, urgent surgery
hould be postponed in patients with severe impaired con-
ciousness.
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